In combination w/ prednisone or prednisolone for metastatic castration resistant prostate cancer in adult men whose disease has progressed on or after docetaxel-based chemotherapy regimen; in asymptomatic or mildly symptomatic adult men after androgen deprivation therapy failure in whom chemotherapy is not yet clinically indicated.
Discontinue use if severe hepatotoxicity develops. HTN, hypokalaemia, fluid retention; severe or unstable angina pectoris, recent MI or ventricular arrhythmia; history of CV disease; decreased bone density; anemia, sexual dysfunction. Hyperglycaemia. Measure serum transaminases prior to, every 2 wk for 1st 3 mth & mthly thereafter. Monitor BP, serum K & fluid retention mthly. Measure blood sugar in diabetic patients frequently. Corticosteroid w/drawal & unusual stress. Avoid use w/ strong CYP3A4 inducers. Patients previously treated w/ ketoconazole. Concomitant use w/ cytotoxic chemotherapy, drugs known to be associated w/ myopathy/rhabdomyolysis. Severe renal & moderate hepatic impairment. Not to be used in severe hepatic impairment. Not to be used in women.
L02BX03 - abiraterone ; Belongs to the class of other hormone antagonists and related agents. Used in the treatment of metastatic castration-resistant prostate cancer.
Manage Account
Change Password
Sign Out
